14 mag 2019
Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis
Aim of this observational study was to assess safety and efficacy of Certolizumab Pegol(CZP) in a real-life cohort of patients affected by psoriasis(PsO) and psoriatic arthritis(PsA), who had an inadequate response to previous systemic immunosuppressive treatments, with a follow-up of 24 weeks.
